Anti-Interferon Auto-Antibodies in Autoimmune Polyendocrinopathy Syndrome Type 1 by Levin, Michael
PLoS Medicine  |  www.plosmedicine.org 0972
 Perspectives 
July 2006  |  Volume 3  |  Issue 7  |  e292
  A
utoimmunity is a common 
mechanism underlying many 
common human diseases. 
Although the mechanisms are not well 
understood, autoimmunity is thought 
to arise from a failure in self-tolerance, 
resulting in a sustained immunological 
attack by speciﬁ  c antibody, T cells, 
or both, directed against antigens 
within the target tissues or organs [1]. 
Many autoimmune disorders appear 
to have a genetic basis, but attempts 
to identify the human genes involved 
have had only limited success, probably 
because of the polygenic nature of 
most common autoimmune disorders, 
and because of the complexity of the 
immunological pathways involved [2].
    Many of the most important clues as 
to the working of the human immune 
system have come from the study of 
patients with rare single gene defects. 
Autoimmune Polyendocrinopathy 
Syndrome Type 1 (APS-1) is a rare, 
recessively inherited disorder, which 
is more common in the Finnish, 
Sardinian, and Iranian Jewish 
populations than in the general 
population[3]. The disorder usually 
presents in early childhood, with 
chronic mucocutaneous candidiasis, 
and adrenal or para-thyroid failure. 
The clinical manifestations of the 
disorder are extremely variable and 
include diabetes, keratitis, chronic 
diarrhoea, alopecia, hepatitis, 
pernicious anaemia, and primary 
hypogonadism [4].
    Immunologically, the disease 
is characterised by lymphocytic 
inﬁ  ltration of the target organs and by 
the presence of auto-antibodies against 
a wide range of tissue-speciﬁ  c antigens 
[5,6]. Mucocutaneous candidiasis 
occurs in all patients with APS-1, but 
the immunological basis of the failure 
to eliminate candida is not understood. 
In general, the defect in elimination 
of candida is not associated with 
defective handling of other pathogens, 
suggesting a candida-speciﬁ  c immune 
defect [7].
    The Molecular Basis of Type 1 APS
    A breakthrough in understanding 
the molecular basis of Type 1 APS 
came from identiﬁ  cation of the 
causative gene by positional cloning 
[8–10]. The novel gene, named   AIRE   
(autoimmune regulator), codes for a 
545–amino acid protein that acts as a 
transcriptional regulator and which 
probably plays a role in regulating 
self-antigen expression in medullary 
thymic epithelial cells and dendritic 
cells [11,12]. Different mutations in 
the coding region of the   AIRE   gene 
are responsible for APS-1 in patients 
carrying homozygous or multiple 
heterozygous mutations [13]. 
    Although the   AIRE   gene deﬁ  nes 
novel pathways controlling self-
tolerance, many questions about 
the immunopathogenesis have 
remained unanswered: 1) the disease 
is extremely variable in its clinical and 
immunological manifestations even in 
patients carrying the same mutation; 
2) the relationship between   AIRE   
mutations and impaired immunity to 
candida remains unknown; and 3) 
how the AIRE protein controls self-
tolerance remains poorly understood. 
    A New Study Shows Antibodies 
against Interferons
    Based on the observation that chronic 
mucocutaneous candidiasis is also 
seen in patients with thymoma and 
myasthenia gravis, in whom high titres 
of antibodies against interferon alpha 
and IL-12 have been found [14], 
Meager and colleagues speculated that 
a similar pathogenic mechanism might 
be involved in patients with APS-1. 
They studied two well-characterised 
cohorts of Finnish and Norwegian 
APS-1 patients, and they reported their 
results in   PLoS Medicine   [15]. Using 
both ELISA-based assays and functional 
interferon neutralising assays, they 
documented high titre IgG auto-
antibodies against Type 1 interferons 
in 100% of patients with APS-1, but not 
in healthy controls, in heterozygous 
carriers of the   AIRE   mutations, or in 
people with other endocrine disorders. 
    The anti-interferon antibodies 
neutralised the biological activity 
of interferon alpha and interferon 
omega, as well as the activity of 
mixed interferons produced in virally 
stimulated cells. The anti-interferon 
antibodies occurred prior to the 
development of other auto-antibodies, 
and in some patients preceded the 
development of clinical features of 
APS-1. 
    Meager and colleagues’ study 
has identiﬁ  ed a novel target of the 
disordered immune response in 
patients with APS-1, and suggests 
a role for Type 1 interferons in 
immune responses to candida and 
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in the regulation of self-tolerance. 
The ﬁ  ndings may have both clinical 
relevance and implications for the 
understanding of the immunological 
events in autoimmunity. The ﬁ  nding 
of anti-interferon antibodies early 
in the course of the disease in 100% 
of patients carrying   AIRE   mutations 
suggests that these antibodies may 
serve as a diagnostic marker of patients 
carrying homozygous   AIRE   mutations.  
These antibodies may therefore be 
useful for screening family members or 
patients with only some features of the 
disorder. The consistent prevalence of 
anti-interferon antibodies in all patients 
with APS from the time of presentation 
suggests that the development of 
these antibodies has been inherited 
concurrently with the   AIRE   mutations, 
behaving as a recessive genetic trait 
with complete penetrance. This raises 
a number of questions about the 
role of these antibodies in the later 
manifestations of the disease. 
    Implications of the Study
    Why should anti-interferon 
antibodies develop with such 
consistency in patients with 
homozygous   AIRE   mutations, and 
what is their signiﬁ  cance in the 
immunopathogenesis of the disorder? 
Impairment of the anti-infective 
properties of Type 1 interferons might 
be expected to result in infection with a 
wide range of opportunistic pathogens. 
However, apart from candida, severe 
infections with other pathogens are 
rare in this disorder. This may suggest 
redundancy in the requirement for 
interferons for most infections (with 
other cytokines compensating for the 
lack of effect of Type 1 interferons). 
Alternatively, Type1 interferons may 
have a speciﬁ  c role in immunity to 
candida not shared by other pathogens. 
Such speciﬁ  city in requirement for 
individual cytokines in immunity is 
seen in the case of patients with defects 
in the interferon gamma and IL-12 
pathways, who are highly susceptible 
to mycobacteria and intracellular 
pathogens while manifesting normal 
immunity to most other organisms 
[16,17].
    As with many important novel 
observations, Meager and colleagues’ 
report raises more questions than 
it answers, and should stimulate 
research to unravel the role of Type 
1 interferons and their antibodies 
in self-tolerance and autoimmunity. 
Does the early appearance of anti-
interferon antibodies suggest a key 
role for interferons in elimination of 
autoreactive T and B cell responses? 
If so, does the impaired interferon 
response play a role in the relentless T 
cell and antibody attack on the other 
tissues and organs occurring in this 
disorder?
    The deﬁ  nitive observation made in 
this report was only possible because 
clinical investigators in several 
countries had assembled large cohorts 
of patients with a rare genetic disorder, 
and had collected clinical samples and 
patient information over a period of 
several decades. At a time when it is 
difﬁ  cult to obtain research funding or 
even ethical approval for long term, 
open-ended clinical research, this 
study is a welcome reminder of the 
importance of long-term follow-up 
of patients with rare diseases. Such 
patients continue to provide unique 
human models through which to gain 
insights into the complex workings of 
the human immune system. While the 
anti-interferon antibodies may have 
immediate clinical use in diagnosis of 
APS-1, unravelling of the mechanisms 
involved in their production, and the 
immunological consequences of their 
presence in the circulation, should be a 
fruitful area for research to understand 
autoimmunity.   
    4.  Ahonen P, Myllarniemi S, Sipila I, Perheentupa 
J (1990) Clinical variation of autoimmune 
polyendocrinopathy-candidiasis-ectodermal 
dystrophy (APECED) in a series of 68 patients. 
N Eng J Med 322: 1829–1836.
    5.  Soderbergh A, Myhre AG, Ekwall O, Gebre-
Medhin G, Hedstrand H, et al. (2004) 
Prevalence and clinical associations of 10 
deﬁ  ned autoantibodies in autoimmune 
polyendocrine syndrome type I. J Clin 
Endocrinol Metab 89: 557–562. 
    6.  Clemente MG, Obermayer-Straub P, Meloni 
A, Strassburg CP, Arangino V, et al. (1997) 
Cytochrome P450 1A2 is a hepatic autoantigen 
in autoimmune polyglandular syndrome type 1. 
J Clin Endocrinol Metab 82: 1353–1361.
    7.  Arulanantham K, Kwyer JM, Genel M (1979) 
Evidence for defective immunoregulation 
in the syndrome of familial candidiasis 
endocrinopathy. N Eng J Med 300: 164–168. 
    8.  Ahonen P (1985) Autoimmune 
polyendocrinopathy–candidosis–ectodermal 
dystrophy (APECED): Autosomal recessive 
inheritance. Clin Genet 27: 535–542. 
    9.  Aaltonen J, Bjorses P, Sandkuijl L, Perheentupa 
J, Peltonen L (1994) An autosomal locus 
causing autoimmune disease: Autoimmune 
polyglandular disease type I assigned to 
chromosome 21. Nat Genet 8: 83–87.
    10. Nagamine K, Peterson P, Scott HS, Kudoh J, 
Minoshima S, et al. (1997) Positional cloning 
of the APECED gene. Nat Genet 17: 393–398.
    11. Finnish–German APECED Consortium (1997) 
An autoimmune disease, APECED, caused by 
mutations in a novel gene featuring two PHD-
type zinc-ﬁ  nger domains. Nat Genet 17: 399-
403. 
    12. Bjorses P, Halonen M, Palvimo JJ, Kolmer 
M, Aaltonen J, et al. (2000) Mutations in the 
AIRE gene: Effects on subcellular location and 
transactivation function of the autoimmune 
polyendocrinopathy-candidiasis-ectodermal 
dystrophy protein. Am J Hum Genet 66: 378–
392. 
    13. Scott HS, Heino M, Peterson P, Mittaz L, 
Lalioti MD, et al. (1998) Common mutations in 
autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy patients of different 
origins. Mol Endocrinol 12: 1112–1119.
    14. Zhang W, Liu JL, Meager A, Newsom-Davis 
J, Willcox N (2003) Autoantibodies to IL-12 
in myasthenia gravis patients with thymoma: 
Effects on the IFN-gamma responses of 
healthy CD4+ T cells. J Neuroimmunol 139: 
102–108.
    15. Meager A, Visvalingam K, Peterson P, 
Möll K, Murumägi A, et al. (2006) Anti-
interferon autoantibodies in autoimmune 
polyendocrinopathy syndrome type 1. 
PLoS Med 3: e289. DOI: 10.1371/journal.
pmed.0030289
    16. Newport MJ, Huxley CM, Huston S, 
Hawrylowicz C, Oostra B, et al. (1996) A 
mutation in the interferon-g-receptor gene and 
susceptibility to mycobacterial infection.  N 
Engl J Med 335: 1941–1949.
    17. Kampmann B, Stephens A, Hemingway 
C, Davidson R, Goodsall A, et al. (2005) 
Acquired immune defect in the handling of 
mycobacteria due to auto antibodies against 
Interferon Gamma. J Clin Invest 115: 2480–
2488. 
  References
    1.  Eisenbarth GS, Gottlieb PA (2004) 
Autoimmune polyendocrine syndromes. N Eng 
J Med 350: 2068–2079. 
    2.  Morahan G, Morel L (2002) Genetics of 
autoimmune diseases in humans and in animal 
models. Curr Opin Immunol 14: 803–811.
    3.  Betterle C, Greggio NA, Volpato M (1998) 
Autoimmune polyglandular syndrome type 1. 
J Clin Endocrinol Metab 83: 1049–055. 
July 2006  |  Volume 3  |  Issue 7  |  e292